Workboat Indexes
All News about Royalty Pharma Plc Cl A
![](https://g.foolcdn.com/editorial/images/789906/investor-sofa-laptop-getty.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/09/04/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
September 03, 2024
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://www.chartmill.com/images/uploads/Undervalued_500_264px_webp_74997b3ff2.webp)
![](https://cdn.benzinga.com/files/images/story/2024/08/16/JimCramer-Shutterstock.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Reports Second Quarter 2024 Results
August 08, 2024
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Declares Third Quarter 2024 Dividend
July 17, 2024
From Royalty Pharma plc
Via GlobeNewswire
![](https://www.investors.com/wp-content/uploads/2024/01/Headshot-RobertBlum-CEO-cytokinetics-company.jpg)
![](https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600.png)
![](https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600.png)
![](https://cdn.benzinga.com/files/images/story/2024/06/12/Interest-Rate-And-Dividend-Yield-Concept.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2020/09/biotech-stocks.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/05/28/Genetic-Research-And-Biotech-Science-Con.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/11/Stock-DrugPharm-44-adobe.jpg)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/05/23/CYTK.png?width=1200&height=800&fit=crop)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
![](https://investorplace.com/wp-content/uploads/2024/04/dividend-stocks1600-4.png)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
From Royalty Pharma plc
Via GlobeNewswire
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
Royalty Pharma Reports First Quarter 2024 Results
May 09, 2024
From Royalty Pharma plc
Via GlobeNewswire
![](https://ml.globenewswire.com/media/d605b3b0-7ba0-46e1-a2d4-439ca98694f8/small/logo-jpg.jpg)
From Royalty Pharma plc
Via GlobeNewswire
![](https://cdn.benzinga.com/files/images/story/2024/05/02/pharmaceutical.jpeg?width=1200&height=800&fit=crop)
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.